Spectrum Pharmaceuticals, Inc.
POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF
Last updated:
Abstract:
Provided are combinations of poziotinib and an anti-HER1, anti-HER2 or anti-HER4 antibody, optionally with other agents, and use of the combinations for treating cancer.
Status:
Application
Type:
Utility
Filling date:
25 Jun 2019
Issue date:
26 Aug 2021